Results 11 to 20 of about 382,649 (338)

Hematopoietic stem cell transplantation [PDF]

Stem Cells and Cloning: Advances and Applications, 2010
Eleftheria Hatzimichael1, Mark Tuthill21Department of Haematology, Medical School of Ioannina, University of Ioannina, Ioannina, Greece; 2Department of Medical Oncology, Hammersmith Hospital, Imperial College National Health Service Trust, London ...
Eleftheria Hatzimichael, Mark Tuthill
doaj   +5 more sources

Hematopoietic Stem Cell Transplantation for Leukemia [PDF]

Pediatric Clinics of North America, 2010
Leukemia represents the most common pediatric malignancy, accounting for approximately 30% of all cancers in children less than 20 years of age. Most children diagnosed with leukemia are cured without hematopoietic stem cell transplantation (HSCT), but for some high-risk subgroups, allogeneic HSCT plays an important role in their therapeutic approach ...
Wayne, A.S., Baird, K., Egeler, R.M.
openaire   +4 more sources

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

Experimental Hematology & Oncology, 2017
Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have
Mauricio Sarmiento Maldonado, Pablo Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Veronica Jara Arias, Katherine Soto Donoso, Pablo Uribe Gonzalez, Mauricio Ocqueteau Tachini, Jose Antonio Perez-Simón   +7 more
doaj   +1 more source

Hematopoietic stem cells for transplantation [PDF]

Nature Immunology, 2002
Multiple sources of HSCs exist. Here, Verfaillie discusses the long-term engraftment capabilities of each source and the search for ex vivo expansion conditions to allow bulk culture for therapeutic HSC transplantation.
openaire   +3 more sources

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Journal of Hematology & Oncology, 2019
The original article [1] contains two errors in the MRD Testing sub-section of the Methods:
Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang   +13 more
doaj   +1 more source

Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene

Experimental Hematology & Oncology, 2023
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a refractory and recurrent subtype of B-cell ALL enriched with kinase-activating rearrangements.
Xuehong Zhang, Zhijie Hou, Dan Huang, Furong Wang, Beibei Gao, Chengtao Zhang, Dong Zhou, Jiacheng Lou, Haina Wang, Yuan Gao, Zhijie Kang, Ying Lu, Quentin Liu, Jinsong Yan   +13 more
doaj   +1 more source

Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives

Frontiers in Pediatrics, 2019
Primary immunodeficiencies (PID) are disorders that for the most part result from mutations in genes involved in immune host defense and immunoregulation.
R. Castagnoli, O. Delmonte, Enrica Calzoni, L. Notarangelo   +3 more
semanticscholar   +1 more source

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Journal of Hematology & Oncology, 2017
Background This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated ...
Ying-Jun Chang, Yu Wang, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Xiao-Jun Huang   +14 more
doaj   +1 more source

Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.

Blood, 2017
Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by ...
E. Gluckman, B. Cappelli, F. Bernaudin, M. Labopin, F. Volt, J. Carreras, Belinda Pinto Simões, A. Ferster, S. Dupont, J. de la Fuente, J. Dalle, M. Zecca, M. Walters, L. Krishnamurti, M. Bhatia, K. Leung, G. Yanik, J. Kurtzberg, N. Dhédin, M. Kuentz, G. Michel, J. Apperley, P. Lutz, B. Neven, Y. Bertrand, J. Vannier, M. Ayas, M. Cavazzana, S. Matthes‐Martin, V. Rocha, Hanadi Elayoubi, C. Kenzey, P. Bader, F. Locatelli, A. Ruggeri, M. Eapen   +35 more
semanticscholar   +1 more source

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Journal of Hematology & Oncology, 2016
Background Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse.
Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang   +13 more
doaj   +1 more source